AlphAIAlphAI — Financial news for AI agents
tradingview.comNOV 22 min read$RXRX

Recursion (RXRX) Reports Further Phase 2 REC-4881 Polyp Reductions

Recursion (RXRX) reported updated Phase 2 TUPELO trial results, showing 47% median reduction in polyp burden after 12 weeks of treatment, with 85% of patients maintaining reductions 12 weeks post-treatment. The company plans to initiate a registrational trial in the second half of 2027, pending FDA discussions.

Original reporting
tradingview.com
Published Nov 2, 2026, 9:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 9:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Recursion (RXRX) Reports Further Phase 2 REC-4881 Polyp Reductions — source image
Source · tradingview.com
Decision brief

The 30-second read

$RXRXBullishMed
01

Why it matters

The data suggest the candidate drug is progressing toward a registrational trial, potentially unlocking future revenue streams.

02

Market read

First-time release of Phase 2 efficacy data provides a fresh catalyst for RXRX, likely influencing short-term price action.

03

What to watch

Regulatory timeline remains uncertain; trial initiation depends on FDA alignment.

Relevance 8/10Novelty 8/10Timing: today

Background

Recursion (RXRX) provided an update from its Phase 2 TUPELO trial in familial adenomatous polyposis, reporting polyp reductions and safety outcomes.

Company-level read

Ticker impact

$RXRXBullishHigh confidence
Context

Recursion disclosed new Phase 2 data showing significant polyp burden reductions and a favorable safety profile, indicating potential regulatory progress.

Expected impact

likely upward pressure as the market prices in the encouraging trial results

Evidence & confidence

First disclosure of Phase 2 efficacy and safety, a material catalyst for a biotech.

Market effects

Sector

Strengthens the FAP therapeutic pipeline and may influence peer biotech valuations.

Regional

U.S. biotech sector could see modest gains.

Global

Limited to biotech investors; no broad market effect.

Counterpoint

What could challenge this read

Data set is small (26 patients); investors may remain cautious until larger trials confirm durability.

Key entities

  • Company
    Recursion Pharmaceuticals

    Biotech firm developing the REC-4881 therapy.

  • Person
    Lisa Boardman, M.D.

    Presenter of the trial data at the CGA-IGC meeting.

Read at source← All news

Also covered by

1 outlet

Related articles

NOV 2
$RXRXMed

Recursion Pharmaceuticals earnings matched, revenue topped estimates

Recursion Pharmaceuticals (RXRX) reported Q3 EPS of $-0.22, matching estimates, with revenue of $18.55M, exceeding the $12.98M consensus. The stock is up 20.44% over 3 months but down 29.60% year-over-year. Analysts have revised EPS estimates twice positively and once negatively in the last 90 days. The company's financial health is rated as 'fair performance' by InvestingPro.

investing.com2 min
NOV 2
$RXRXMedAI 9/10

Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi…

RECURSION PHARMACEUTICALS, INC. (RXRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair • New Phase 2 REC-4881 data presented at CGA-IGC in

SEC EDGAR 8-K7 min
NOV 2
$RXRXMedAI 8/10

Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair

Recursion (RXRX) reported Q3 2026 results, extending cash runway to 2029. REC-4881 showed deep, durable polyp burden reductions in FAP, with activity across the GI tract. REC-1245 demonstrated early clinical signals in cancer. Sanofi optioned a development candidate. Fred Hassan appointed as Chair. Company reiterated 2026 and 2027 cash operating expense guidance.

globenewswire.com7 min
NOV 2
$RXRXMedAI 8/10

Recursion reports positive Phase 2 data for FAP treatment

Recursion (RXRX) reported positive Phase 2 data for REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). After 12 weeks, patients saw a 47% median reduction in polyp burden, with 85% remaining below baseline 12 weeks post-treatment. The safety profile was consistent with the MEK inhibitor class. Recursion aims to start a registrational trial in late 2027, with FDA Orphan Drug and Fast Track designations already secured.

investing.com2 min
NOV 2
$RXRXMedAI 8/10

Two patients each went from over 90 large polyps to one

Recursion (RXRX) reported positive Phase 2 data from the TUPELO trial of REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). After 12 weeks, patients saw a 47% median reduction in polyp burden, with 85% remaining below baseline 12 weeks post-treatment. Two patients reduced their larger polyp counts from over 90 to one. No new safety signals were observed. The company plans to initiate a registrational trial in 2027, pending FDA discussions.

stocktitan.net2 min
OCT 28
$RXRXHighAI 8/10

RXRX Stock Jumps As Sanofi Deal And Trial Data Ignite AI Drug Story

Recursion Pharmaceuticals (RXRX) stock rose 7.04% on October 28, 2026, driven by positive clinical trial data, a Sanofi deal, and a $200M equity raise. The company reported encouraging results for REC-4881 and REC-1245, while Sanofi's option exercise brought total payments to $144M. RXRX has a market cap of $74.3M, a price-to-sales ratio of 43, and significant cash reserves.

stockstotrade.com3 min